Go Centro Medico San Nicolás

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Obesity5 trials
• Type 2 diabetes4 trials
• Chronic kidney disease2 trials
• Peripheral artery disease2 trials
• Stroke2 trials
• Coronary artery disease1 trial
• Heart failure1 trial
• Metastatic breast cancer1 trial
• Osteoarthritis1 trial

Phase

• Phase 38 trials
• Phase 21 trial

Status

• Recruiting4 trials
• Active, not recruiting3 trials
• Not yet recruiting2 trials

Lead sponsor

• Eli Lilly and Company9 trials

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

  Contact: Paulina Lanchiotti (principal investigator)

• Recruiting

  Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  NCT07353931· Phase 3· Eli Lilly and Company· Source

  Contact: Paulina Lanchiotti (principal investigator)

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

  Contact: Vanina Binner (principal investigator)

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

  Contact: Paulina Lanchiotti (principal investigator)

• Recruiting

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· Phase 3· Eli Lilly and Company· Source

  Contact: Paulina Lanchiotti (principal investigator)

• Active, not recruiting

  A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  NCT07215559· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

  NCT06739122· Phase 3· Eli Lilly and Company· Source

  Contact: Paulina Lanchiotti (principal investigator)

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Type 2 diabetes2 recruiting
• Chronic kidney disease1 recruiting
• Metastatic breast cancer1 recruiting
• Osteoarthritis1 recruiting
• Peripheral artery disease1 recruiting
• Stroke1 recruiting